A Phase 1 interventional study of Vonoprazan ODT-1 or ODT-2 without Water and Vonoprazan ODT-1 or ODT-2 with Water in Healthy Volunteers, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Phathom Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy participants.
Phathom Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 11 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Drug: Vonoprazan ODT-1 or ODT-2 without Water · Drug: Vonoprazan ODT-1 or ODT-2 with Water · Drug: Vonoprazan (Reference)
Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Drug: Vonoprazan ODT-1 or ODT-2 without Water · Drug: Vonoprazan ODT-1 or ODT-2 with Water · Drug: Vonoprazan (Reference)
Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Drug: Vonoprazan ODT-1 or ODT-2 without Water · Drug: Vonoprazan ODT-1 or ODT-2 with Water · Drug: Vonoprazan (Reference)
Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Drug: Vonoprazan ODT-1 or ODT-2 without Water · Drug: Vonoprazan ODT-1 or ODT-2 with Water · Drug: Vonoprazan (Reference)
Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Drug: Vonoprazan ODT-1 or ODT-2 without Water · Drug: Vonoprazan ODT-1 or ODT-2 with Water · Drug: Vonoprazan (Reference)
Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water
Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe
Vonoprazan will be administered orally as a tablet
Maximum Observed Drug Concentration (Cmax) of Vonoprazan
Cmax of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan
AUC0-t of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan
AUC0-inf of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan
Tmax of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan
Tlag of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Terminal Elimination Rate Constant (λz) of Vonoprazan
λz of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Terminal Phase Half-life (t1/2) of Vonoprazan
t1/2 of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Apparent Oral Clearance (CL/F) of Vonoprazan
CL/F of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Apparent Volume of Distribution (Vz/F) of Vonoprazan
Vz/F of Vonoprazan was reported.
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
This study was conducted at single center in the United States from 14 February 2025 to 10 April 2025.
| Milestone | Vonoprazan 10 mg: Treatment Sequence 1 | Vonoprazan 10 mg: Treatment Sequence 2 | Vonoprazan 10 mg: Treatment Sequence 3 | Vonoprazan 10 mg: Treatment Sequence 4 | Vonoprazan 10 mg: Treatment Sequence 5 |
|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Cmax of Vonoprazan was reported.
| nanogram per milliliter (ng/mL) | Treatment A: Vonoprazan 10 mg | Treatment B: Vonoprazan 10 mg | Treatment C: Vonoprazan 10 mg | Treatment D: Vonoprazan 10 mg | Treatment E: Vonoprazan 10 mg |
|---|---|---|---|---|---|
| Maximum Observed Drug Concentration (Cmax) of Vonoprazan | 6.11 ± 47.8 | 5.81 ± 41.4 | 5.46 ± 36.1 | 5.72 ± 46.2 | 5.40 ± 38.4 |
AUC0-t of Vonoprazan was reported.
| ng*hour/mL | Treatment A: Vonoprazan 10 mg | Treatment B: Vonoprazan 10 mg | Treatment C: Vonoprazan 10 mg | Treatment D: Vonoprazan 10 mg | Treatment E: Vonoprazan 10 mg |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan | 57.1 ± 45.8 | 54.8 ± 42.0 | 52.8 ± 41.7 | 51.7 ± 47.6 | 49.8 ± 38.5 |
AUC0-inf of Vonoprazan was reported.
| ng*hour/mL | Treatment A: Vonoprazan 10 mg | Treatment B: Vonoprazan 10 mg | Treatment C: Vonoprazan 10 mg | Treatment D: Vonoprazan 10 mg | Treatment E: Vonoprazan 10 mg |
|---|---|---|---|---|---|
| AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan | 59.2 ± 44.3 | 57.1 ± 39.4 | 55.3 ± 39.0 | 54.1 ± 44.9 | 51.9 ± 36.3 |
Tmax of Vonoprazan was reported.
| hours | Treatment A: Vonoprazan 10 mg | Treatment B: Vonoprazan 10 mg | Treatment C: Vonoprazan 10 mg | Treatment D: Vonoprazan 10 mg | Treatment E: Vonoprazan 10 mg |
|---|---|---|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan | 2.00 (1.50 to 6.00) | 2.00 (1.50 to 6.00) | 2.12 (1.50 to 4.08) | 2.00 (1.50 to 6.00) | 2.00 (1.00 to 6.00) |
Tlag of Vonoprazan was reported.
| hours | Treatment A: Vonoprazan 10 mg | Treatment B: Vonoprazan 10 mg | Treatment C: Vonoprazan 10 mg | Treatment D: Vonoprazan 10 mg | Treatment E: Vonoprazan 10 mg |
|---|---|---|---|---|---|
| Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan | 0.32 (0.25 to 1.02) | 0.25 (0.25 to 1.00) | 0.32 (0.25 to 1.00) | 0.25 (0.25 to 1.50) | 0.27 (0.25 to 1.50) |
λz of Vonoprazan was reported.
| per hour | Treatment A: Vonoprazan 10 mg | Treatment B: Vonoprazan 10 mg | Treatment C: Vonoprazan 10 mg | Treatment D: Vonoprazan 10 mg | Treatment E: Vonoprazan 10 mg |
|---|---|---|---|---|---|
| Terminal Elimination Rate Constant (λz) of Vonoprazan | 0.0948 ± 0.0175 | 0.0998 ± 0.0188 | 0.0955 ± 0.0167 | 0.0963 ± 0.0140 | 0.0975 ± 0.0185 |
t1/2 of Vonoprazan was reported.
| hours | Treatment A: Vonoprazan 10 mg | Treatment B: Vonoprazan 10 mg | Treatment C: Vonoprazan 10 mg | Treatment D: Vonoprazan 10 mg | Treatment E: Vonoprazan 10 mg |
|---|---|---|---|---|---|
| Terminal Phase Half-life (t1/2) of Vonoprazan | 7.54 ± 1.36 | 7.20 ± 1.42 | 7.48 ± 1.38 | 7.36 ± 1.22 | 7.35 ± 1.36 |
CL/F of Vonoprazan was reported.
| litres/hour (L/h) | Treatment A: Vonoprazan 10 mg | Treatment B: Vonoprazan 10 mg | Treatment C: Vonoprazan 10 mg | Treatment D: Vonoprazan 10 mg | Treatment E: Vonoprazan 10 mg |
|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) of Vonoprazan | 184 ± 78.9 | 188 ± 76.0 | 193 ± 72.5 | 202 ± 89.2 | 205 ± 75.9 |
Vz/F of Vonoprazan was reported.
| litres (L) | Treatment A: Vonoprazan 10 mg | Treatment B: Vonoprazan 10 mg | Treatment C: Vonoprazan 10 mg | Treatment D: Vonoprazan 10 mg | Treatment E: Vonoprazan 10 mg |
|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Vonoprazan | 1930 ± 735 | 1880 ± 622 | 2030 ± 678 | 2070 ± 762 | 2100 ± 668 |
Collected over Day 1 to Day 28. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Vonoprazan 10 mg | 0/25 (0%) | 0/25 (0%) | 2/25 (8%) |
| Treatment B: Vonoprazan 10 mg | 0/25 (0%) | 0/25 (0%) | 0/25 (0%) |
| Treatment C: Vonoprazan 10 mg | 0/25 (0%) | 0/25 (0%) | 1/25 (4%) |
| Treatment D: Vonoprazan 10 mg | 0/25 (0%) | 0/25 (0%) | 1/25 (4%) |
| Treatment E: Vonoprazan 10 mg | 0/25 (0%) | 0/25 (0%) | 1/25 (4%) |
| Event | Treatment A: Vonoprazan 10 mg | Treatment B: Vonoprazan 10 mg | Treatment C: Vonoprazan 10 mg | Treatment D: Vonoprazan 10 mg | Treatment E: Vonoprazan 10 mg |
|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/25 | 0/25 | 1/25 | 0/25 | 0/25 |
| NauseaGastrointestinal disorders | 0/25 | 0/25 | 0/25 | 0/25 | 1/25 |
| VomitingGastrointestinal disorders | 0/25 | 0/25 | 0/25 | 0/25 | 1/25 |
| DizzinessNervous system disorders | 1/25 | 0/25 | 0/25 | 0/25 | 0/25 |
| Dry skinSkin and subcutaneous tissue disorders | 0/25 | 0/25 | 0/25 | 1/25 | 0/25 |
| ErythemaSkin and subcutaneous tissue disorders | 0/25 | 0/25 | 0/25 | 1/25 | 0/25 |
The safety population included all participants who receive at least 1 dose of study drug. As planned, baseline data was collected and reported as single arm for all 25 participants.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 37.2 ± 8.66 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 15 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 16 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2025 to primary completion in Apr 2025, 1 month.
Results were first posted in Dec 2025, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan
Phathom Pharmaceuticals, Inc.